CONTEXT: Refractory acute myeloid leukemia (AML) is a difficult disease to control with second or thirdline chemotherapy regimens. In this report, we describe using azacitidine in combination with lenalidomide as salvage therapy. CASE REPORT: 52-year-old female was diagnosed with refractory AML and high-risk cytogenetics: complex monosomal karyotype consisting of t (3, 3) in association with monosomy 7 and del 5q. Morphological remission associated with maintenance of the cytogenetic abnormality of chromosome 3 and disappearance of the abnormalities relating to chromosomes 5 and 7 was achieved after three cycles of combination therapy with azacitidine and lenalidomide. CONCLUSION: Azacitidine plus lenalidomide can be a therapeutic option for patients with refractory AML, as illustrated in this case.
CITATION STYLE
Todaro, J., Bollmann, P. W., Rother, E. T., & del Giglio, A. (2015). Azacitidina e lenalidomida como alternativa de tratamento para leucemia mieloide aguda refratária: Um relato de caso. Sao Paulo Medical Journal, 133(3), 271–274. https://doi.org/10.1590/1516-3180.2012.6790006
Mendeley helps you to discover research relevant for your work.